IL1A and Parkinson disease: Consistent with a detrimental role for IL-1β, IL-1 KO mice (null for both IL-1α and IL-1β) and IL-1R1 KO mice were protected from PD pathology following intranigral [74], intraperitoneal [75] and intranasal [76] administration of LPS, respectively.